Forced degradation studies of new formulation containing naltrexone

Abstract

Naltrexone is one of the classical opioid antagonists. In substantially lower than standard doses, they apply different pharmacodynamics. A daily dose of 1 to 5 mg is considered as low-dose naltrexone (LDN). Clinical reports of LDN have demonstrated its possible benefits in diseases such as fibromyalgia, Crohn’s disease, multiple sclerosis, complex-regional pain syndrome, Hailey-Hailey disease, and cancer.